San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Cardiff Oncology is raising $2,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Erlander played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cardiff Oncology

Cardiff Oncology is is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring« (PCM) technology in tumor genomics. Cardiff Oncology has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Cardiff Oncology offers its PCM technology at its CLIA/CAP accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.

To learn more about Cardiff Oncology, visit http://cardiffoncology.com/

Contact:
Mark Erlander, Chief Executive Officer
858-952-7570
https://www.linkedin.com/in/mark-erlander-ph-d-33669269/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved